The board stated in a statement issued on Friday, May 20, that the public was overusing Nonsteroidal Anti-Inflammatory Drug (NSAID) for pain management.
It was emphasized that using Diclofenac at high doses and for long periods of time is associated with an increased risk of blood clots in the arteries, particularly in patients with underlying heart or circulatory conditions or with certain cardiovascular risk factors.
"It has resulted in heart attacks and strokes in some cases."
"Diclofenac is a widely used pain and inflammation reliever, particularly in painful conditions such as arthritis." Overall, the benefits of diclofenac outweigh the risks," the PPB cautioned.
Individuals who use high doses (150 mg daily) for long periods of time are at risk of having a heart attack or stroke, according to the board.
Patients with a history of heart attack or stroke, heart failure, blood vessel blockages to the heart or brain, or who have had an operation to clear or bypass such blockages, or circulatory problems that restrict blood flow to your limbs, should not take the drug.
Content created and supplied by: CarolKibet (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More